Mark Shamoun
Merck & Co., Inc., Rahway, NJ, USA (United States) · 21 works · 224 citations · h-index 7
Top works
- Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron
- Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up
- Efficacy and Safety of Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Unresponsive to Oral Iron Therapy
- Mexiletine: An adjuvant option for refractory pain in patients with sickle cell disease and comorbid autism spectrum disorder
- Childhood B-Cell Acute Lymphoblastic Leukemia Following SARS CoV-2 Infection: A Potential Second “Hit” in Leukemogenesis
- Characterizing bulk rigidity of rigid red blood cell populations in sickle-cell disease patients
- OA14.05 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%
- CD14/16 monocyte profiling in juvenile myelomonocytic leukemia
- The Effect of Azithromycin on Relapse in Patients with Moderate-Severe Chronic Graft Versus Host Disease (CGVHD)
- Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors
- The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC
- Characterization of Bulk Rigidity of Rigid Red Blood Cell Populations in Sickle Cell Patients Using a Parameterization Model of Ektacytometry
- Thalassemia
- The Effect of Rigid Red Blood Cells on Platelet Adhesion in Blood Flow and Implications in Sickle Cell Disease
- Abstract CT282: MK-2870-004: A phase 3 study of MK-2870 (SKB264) versus chemotherapy for previously treated advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) with EGFR mutations or other genomic alterations
- P2.10A.06 Phase 3 TroFuse-004 Study: Sac-TMT vs Chemotherapy for Previously Treated Advanced NSCLC with EGFR/Other Genomic Alterations
- MA11.07 Pembrolizumab Plus Maintenance Olaparib as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 KEYLYNK-006 Study
- Response to: Enhancing Clinical Practice: Critical Insights for Medical Workers in Applying Pembrolizumab for Metastatic NSCLC and Pembrolizumab, Chemotherapy and Metastatic Non-Small Cell Lung Cancer
- 2081eTiP KEYMAKER-U01 phase II substudies 01H/01I: Ifinatamab deruxtecan (I-DXd), raludotatug deruxtecan (R-DXd), or docetaxel in stage IV non-small cell lung cancer (NSCLC)
- Hypercoagulation and Pediatric Inflammatory Bowel Disease